Mubadala Bio launches eight locally produced essential medicines in UAE

The newly launched medicines include high-demand therapies widely used by patients

Last updated: October 22, 2025 | 16:04

2 MIN READ

The company manufactures and distributes over 10,000 products to more than 100 countries worldwide.

Supplied

As part of its commitment to advancing national drug security, Mubadala Bio has introduced eight new essential medicines in the UAE through its subsidiaries. This milestone underscores the company’s mission to deliver improved health outcomes for patients across the UAE and the wider region.

The announcement marks significant progress in supporting the UAE’s vision to become a regional hub for life sciences—enhancing drug security, improving access to essential medicines, and driving the growth of a sustainable, knowledge-based economy.

Also Read: UAE launches new contact centre for medicines, boosts patient access

Also Read: Mubadala Bio appoints new CEO, announces top leadership changes

Also Read: Abu Dhabi's Mubadala re-invests in its 'top-performing' healthcare asset

Also Read: Borouge, Mubadala Bio join forces to boost UAE’s healthcare manufacturing

The newly launched medicines include high-demand therapies widely used in hospitals, clinics, and by patients nationwide:

Rivaroxaban – an anticoagulant used to prevent blood clots in the brain and other blood vessels
Linezolid – an essential antibiotic for treating drug-resistant bacterial infections
Sugammadex – used for anesthesia recovery following surgery
Fluconazole – an antifungal treatment for serious fungal infections
Pantoprazole (injectable) – reduces stomach acid
Ondansetron (injectable) – prevents nausea and vomiting, primarily related to cancer treatment
Bupivacaine – a long-acting local anesthetic for pain control
Sodium Chloride Inhalation Solution – clears airways and helps remove mucus from the lungs

Now locally produced at Mubadala Bio’s UAE facilities — Gulf Inject, Wellpharma, and Bioventure Healthcare — these medications address growing national demand for essential therapies while strengthening the UAE’s capacity to ensure reliable and uninterrupted access to critical medical supplies.

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, said: “As a national champion, Mubadala Bio was established to strengthen the UAE’s life sciences sector and enable the local production of essential medications. With the launch of these products, we are delivering on this commitment — ensuring a continuous and reliable supply of key medical therapies within the country.”

Dr. Essam Mohamed, CEO of Mubadala Bio, added “We are pleased to introduce new locally manufactured medications that support healthcare providers and patients across the UAE. These launches reflect our long-term commitment to expanding the nation’s life sciences capabilities and enhancing self-sufficiency in healthcare manufacturing.”

Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, stated: “With these launches, Mubadala Bio is not only meeting today’s needs but also shaping the future of the life sciences industry in the UAE and the region. We are dedicated to delivering transformative health outcomes and to positioning Mubadala Bio as a global leader in the sector.”

Mubadala Bio currently owns and operates 10 pharmaceutical assets across Asia, Africa, and Europe — including six in the UAE — with the capacity to manufacture various dosage forms, such as tablets, capsules, small- and large-volume IV injectables, and eye and ear drops. The company manufactures and distributes over 10,000 products to more than 100 countries worldwide.

Abdulla RasheedEditor - Abu Dhabi

Abdullah Rashid Al Hammadi  is an accomplished Emirati journalist with over 45 years of experience in both Arabic and English media. He currently serves as the Abu Dhabi Bureau Chief fo Gulf News. Al Hammadi began his career in 1980 with Al Ittihad newspaper, where he rose through the ranks to hold key editorial positions, including Head of International News, Director of the Research Center, and Acting Managing Editor. A founding member of the UAE Journalists Association and a former board member, he is also affiliated with the General Federation of Arab Journalists and the International Federation of Journalists. Al Hammadi studied Information Systems Technology at the University of Virginia and completed journalism training with Reuters in Cairo and London. During his time in Washington, D.C., he reported for Alittihad  and became a member of the National Press Club. From 2000 to 2008, he wrote the widely read Dababees column, known for its critical take on social issues. Throughout his career, Al Hammadi has conducted high-profile interviews with prominent leaders including UAE President His Highness Sheikh Mohamed bin Zayed Al Nahyan, HH Sheikh Mohammed bin Rashid Al Maktoum, and key Arab figures such as the late Yasser Arafat and former presidents of Yemen and Egypt. He has reported on major historical events such as the Iran-Iraq war, the liberation of Kuwait, the fall of the Berlin Wall, and the establishment of the Palestinian Authority. His work continues to shape and influence journalism in the UAE and the wider Arab world.

Get the latest news and updates straight to your inbox

Up Next